Targeting mast cell as a neuroprotective strategy.
Umut OcakPinar Eser OcakAnnie WangJohn H ZhangWarren BolingPei WuJun MoTongyu ZhangLei HuangPublished in: Brain injury (2018)
Background: Mast cells (MCs) are perivascularly located immune cells of haematopoietic origin. Emerging evidences suggest that the activation of MCs play important roles in the pathogenesis of blood brain barrier disruption, neuroinflammation, and neurodegeneration. Objectives: In this review, we aimed to discuss the detrimental effects of MCs in response to various types of brain injury, as well as the therapeutic potential and neuroprotective effects of targeting the activation and degranulation of MCs, particularly in the management of the acute phase. Methods: An extensive online literature search was conducted through Pubmed/Central on March 2018. Then, we comprehensively summarized the effects of the activation of brain MCs in acute brain injury along with current pharmacological strategies targeting at the activation of MCs. Results: The review of the current literature indicated that the activation and degranulation of brain MCs significantly contribute to the acute pathological process following different types of brain injury including focal and global cerebral ischaemia, intracerebral haemorrhage, subarachnoid haemorrhage, and traumatic brain injury. Conclusions: Brain MCs significantly contribute to the acute pathological processes following brain injury. In that regard, targeting brain MCs may provide a novel strategy for neuroprotection.
Keyphrases
- brain injury
- cerebral ischemia
- subarachnoid hemorrhage
- blood brain barrier
- traumatic brain injury
- liver failure
- cancer therapy
- systematic review
- respiratory failure
- drug induced
- resting state
- social media
- healthcare
- intensive care unit
- hepatitis b virus
- cognitive impairment
- acute respiratory distress syndrome
- cerebral blood flow